Oncology - European Medical Journal

Continue

Oncology

Filter
EMJ
17 Apr 2015

Evidence Grows That Melanoma Drugs Benefit Some Lung Cancer Patients

Geneva, Switzerland, 17 April 2015 — A subset of lung cancer patients can derive important clinical benefits from drugs that are more commonly used to…
EMJ
17 Apr 2015

New Real-World Clinical Practice Study Highlights the Value of the Oncotype DX® Breast Cancer Test for Patients, Physicians and the Health Care System

Studies present results from a real-life observational study in Ireland demonstrating significant reductions in chemotherapy and resulting cost-savings when the test is used in early stage breast cancer.
EMJ
25 Feb 2015

Living with a Rare Cancer

Lugano, 25 February 2015 – Within the “umbrella” of rare diseases, rare cancer patients confront particular problems. Most rare diseases have an…
EMJ
23 Feb 2015

Combination Therapy Trial for Breast Cancer

BREAST cancer patients with small node-negative HER2-positive tumours achieved 3-year survival approaching 100% with adjuvant paclitaxel and trastuzumab…
EMJ
23 Feb 2015

Anti-Cancer Transformers: The next Generation Self-Assembling Arsenal

PROGRAMMABLE biomaterial that is capable of spontaneously assembling into a fighting structure once injected into a living body has the potential to…
EMJ
13 Jan 2015

A Tribute to Dr Patrick Francis O’Dwyer

A brand new year is at our fingertips and with it comes a new opportunity to explore additional avenues regarding the issue of men’s health awareness.
EMJ
16 Dec 2014

New Oncotype DX® Data Presented at 2014 San Antonio Breast Cancer Symposium Further Demonstrate the Practice-Changing Impact of the Test in Guiding the Treatment of Early Stage Breast Cancer

GENEVA, Switzerland, [December 15, 2014] – Genomic Health announced presentation of the first prospective outcomes data from a large adjuvant study…
EMJ
11 Dec 2014

Gilead Presents Follow-Up Data from Idelalisib (Zydelig®) Registrational Studies in Patients with Chronic Lymphocytic Leukemia, Follicular Lymphoma and Small Lymphocytic Lymphoma

San Francisco, December 10, 2014 – Gilead Sciences, Inc. (Nasdaq: GILD) today announced long-term follow-up results from the registration studies…
We’ve noticed you’re accessing
from North/South America.